Alumis Inc. Common Stock


Market Cap: 677M


About: Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %
of 7 articles

Fund manager confidence

Research analyst outlook

We haven’t received any recent analyst ratings for ALMS.

Financial journalist opinion

Based on 7 articles about ALMS published over the past 30 days